ImmunityBio, Inc.
IBRX
$7.25
$0.081.12%
NASDAQ
Recommendation
Dividend Power Score
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 44.17M | 38.27M | 31.78M | 26.42M | 16.51M |
| Total Other Revenue | 39.00K | 13.00K | 281.00K | 4.00K | 8.00K |
| Total Revenue | 44.21M | 38.29M | 32.06M | 26.43M | 16.52M |
| Cost of Revenue | 238.00K | 382.00K | 177.00K | 136.00K | 58.00K |
| Gross Profit | 43.97M | 37.90M | 31.88M | 26.29M | 16.46M |
| SG&A Expenses | 45.77M | 35.33M | 37.38M | 43.44M | 32.65M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 114.00M | 102.97M | 87.69M | 97.71M | 80.95M |
| Operating Income | -69.79M | -64.68M | -55.63M | -71.29M | -64.43M |
| Income Before Tax | -632.79M | -62.09M | -67.31M | -92.31M | -129.90M |
| Income Tax Expenses | 9.00K | -135.00K | -35.00K | 269.00K | -234.00K |
| Earnings from Continuing Operations | -632.80M | -61.96M | -67.27M | -92.57M | -129.67M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 15.00K | 14.00K | 21.00K | 19.00K | 20.00K |
| Net Income | -632.78M | -61.94M | -67.25M | -92.56M | -129.65M |
| EBIT | -69.79M | -64.68M | -55.63M | -71.29M | -64.43M |
| EBITDA | -65.41M | -60.92M | -51.68M | -67.41M | -60.60M |
| EPS Basic | -0.62 | -0.06 | -0.07 | -0.10 | -0.15 |
| Normalized Basic EPS | -0.38 | -0.04 | -0.04 | -0.06 | -0.10 |
| EPS Diluted | -0.62 | -0.06 | -0.07 | -0.10 | -0.15 |
| Normalized Diluted EPS | -0.38 | -0.04 | -0.04 | -0.06 | -0.10 |
| Average Basic Shares Outstanding | 1.03B | 989.68M | 946.60M | 888.22M | 853.16M |
| Average Diluted Shares Outstanding | 1.03B | 989.68M | 946.60M | 888.22M | 853.16M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |